AU2023238896A1 - Mglur5 modulating compounds, compositions, and methods of use - Google Patents
Mglur5 modulating compounds, compositions, and methods of use Download PDFInfo
- Publication number
- AU2023238896A1 AU2023238896A1 AU2023238896A AU2023238896A AU2023238896A1 AU 2023238896 A1 AU2023238896 A1 AU 2023238896A1 AU 2023238896 A AU2023238896 A AU 2023238896A AU 2023238896 A AU2023238896 A AU 2023238896A AU 2023238896 A1 AU2023238896 A1 AU 2023238896A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- degrees
- solvate
- solvate form
- peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263322446P | 2022-03-22 | 2022-03-22 | |
| US63/322,446 | 2022-03-22 | ||
| PCT/US2023/015966 WO2023183428A1 (en) | 2022-03-22 | 2023-03-22 | Mglur5 modulating compounds, compositions, and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023238896A1 true AU2023238896A1 (en) | 2024-10-03 |
Family
ID=88101942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023238896A Pending AU2023238896A1 (en) | 2022-03-22 | 2023-03-22 | Mglur5 modulating compounds, compositions, and methods of use |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250230149A1 (https=) |
| EP (1) | EP4496572A4 (https=) |
| JP (1) | JP2025509988A (https=) |
| KR (1) | KR20250008042A (https=) |
| CN (1) | CN119300827A (https=) |
| AU (1) | AU2023238896A1 (https=) |
| CA (1) | CA3246263A1 (https=) |
| IL (1) | IL315809A (https=) |
| WO (1) | WO2023183428A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025080252A1 (en) * | 2023-10-13 | 2025-04-17 | Allyx Therapeutics, Inc. | Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one |
| WO2025188734A1 (en) * | 2024-03-06 | 2025-09-12 | Allyx Therapeutics, Inc. | Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691821B2 (en) * | 2010-11-11 | 2014-04-08 | Bristol-Myers Squibb Company | Oxazolidinones as modulators of mGluR5 |
-
2023
- 2023-03-22 IL IL315809A patent/IL315809A/en unknown
- 2023-03-22 US US18/849,063 patent/US20250230149A1/en active Pending
- 2023-03-22 CA CA3246263A patent/CA3246263A1/en active Pending
- 2023-03-22 EP EP23775625.9A patent/EP4496572A4/en active Pending
- 2023-03-22 WO PCT/US2023/015966 patent/WO2023183428A1/en not_active Ceased
- 2023-03-22 JP JP2024556189A patent/JP2025509988A/ja active Pending
- 2023-03-22 KR KR1020247034686A patent/KR20250008042A/ko active Pending
- 2023-03-22 CN CN202380041964.8A patent/CN119300827A/zh active Pending
- 2023-03-22 AU AU2023238896A patent/AU2023238896A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023183428A8 (en) | 2023-12-14 |
| KR20250008042A (ko) | 2025-01-14 |
| CA3246263A1 (en) | 2023-09-28 |
| EP4496572A1 (en) | 2025-01-29 |
| US20250230149A1 (en) | 2025-07-17 |
| CN119300827A (zh) | 2025-01-10 |
| JP2025509988A (ja) | 2025-04-11 |
| EP4496572A4 (en) | 2026-03-11 |
| WO2023183428A1 (en) | 2023-09-28 |
| IL315809A (en) | 2024-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10584122B2 (en) | Solid forms of a compound modulating kinases | |
| US20250230149A1 (en) | Mglur5 modulating compounds, compositions, and methods of use | |
| TWI791507B (zh) | 使用ccr3-抑制劑治療老化相關損傷之方法及組合物 | |
| US20080014259A1 (en) | Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same | |
| TW201720438A (zh) | 用於治療醫學病症之化合物 | |
| JP2021536511A (ja) | ダニコパンの形態 | |
| US20200390737A1 (en) | Nanosuspensions of salsalate and methods of using the same | |
| WO2009008890A1 (en) | METHODS OF MODIFYING AMYLOID β OLIGOMERS USING NON-PEPTIDIC COMPOUNDS | |
| TW201513859A (zh) | 瞼板腺功能障礙之治療劑 | |
| US20240189277A1 (en) | Ophthalmic formulations for sustained neuroprotection | |
| IL268092B2 (en) | Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use | |
| CN110214146B (zh) | 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物 | |
| JP2023107900A (ja) | 標的治療剤 | |
| EP4731205A2 (en) | Solid forms of posiphen d-tartrate | |
| CN113330007A (zh) | 尼拉帕利游离碱的晶体形式 | |
| JP2005511639A (ja) | 虚血性疾患の治療用ドパミン再取り込み阻害活性を有するトロパン誘導体 | |
| JP7048629B2 (ja) | 医薬組成物およびその使用 | |
| RS66516B1 (sr) | 3-sulfopropanska kiselina za lečenje neurodegenerativnih poremećaja | |
| WO2025080252A1 (en) | Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one | |
| AU2023468841A1 (en) | Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one | |
| US11382875B2 (en) | Methods and compositions for modulating β-amyloid/α7-nAChR interactions | |
| WO2025188734A1 (en) | Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one | |
| KR20140146036A (ko) | 피롤로퀴놀리닐-피롤리딘-2,5-디온 제제 및 이의 제조 및 사용 방법 | |
| WO2024027752A1 (zh) | 包含杂环化合物的药物组合物及其制备方法和应用 | |
| KR102065236B1 (ko) | 속방형 덱사메타손 및 서방형 온단세트론을 포함하는 1일 1회 복합 구강 속붕해정 및 이의 제조방법 |